Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

FDA approves new treatment option for prostate cancer

Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration.

30 Apr 2010

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

New theory on muscle and bone diseases

Traditionally, doctors and clinicians thought diseases that affect muscles or bones affected those areas specifically. For example, bone diseases only affect bones, or muscle diseases only concerned muscles. But recent evidence supports the notion that bones and muscles are more interconnected than previously thought.

29 Apr 2010

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.

29 Apr 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.

28 Apr 2010

Potential new treatment for osteonecrosis

28 Apr 2010

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.

28 Apr 2010

Researchers link vitamin D deficiency to chronic fatigue in post-TBI sufferers

New evidence presented at the European Congress of Endocrinology has shown that vitamin D deficiency is closely associated with the chronic fatigue that often follows post traumatic brain injury.

28 Apr 2010

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives - experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

28 Apr 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Usually when all else fails with a technical device, a "reset" button can be pressed, preventing a glitch from going any further. What if that could be done with threats to a person's health? Investigators from The Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have discovered that a form of a dietary trace element known as selenium can help reset a cell's "biological clock" when it is disrupted by a chemical cancer-causing agent (carcinogen).

28 Apr 2010

Laughter is truly the best medicine says new research

A new study has shown that laughter may be one of the simplest exercises that has similar effects on the body as pumping iron in the gym. Researchers have named “Laughercise” as significant elevators of mood, stress busters, immunity boosters and blood pressure and cholesterol reducers. It can also stimulate appetite for the malnourished.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Antares Pharma, Inc., a leader in self-injection drug delivery technology and Uman Pharma, a manufacturer of top-quality injectable pharmaceutical products based in Quebec, Canada, today announced the formation of a strategic alliance covering Antares' VIBEX™ MTX.

27 Apr 2010

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease, today announced the launch of the DaVita Phosphorus Challenge, an online resource designed to serve as a core learning tool for CKD and dialysis patients.

27 Apr 2010

Laughter increases production of antibodies and activates body's protective cells

Laughter is a highly complex process. Joyous or mirthful laughter is considered a positive stress (eustress) that involves complicated brain activities leading to a positive effect on health. Norman Cousins first suggested the idea that humor and the associated laughter can benefit a person's health in the 1970s. His ground-breaking work, as a layperson diagnosed with an autoimmune disease, documented his use of laughter in treating himself—with medical approval and oversight—into remission.

27 Apr 2010

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Ipsen, a global biopharmaceutical group, and Invida Group, the leading healthcare commercialization solutions partner in the Asia Pacific region, announced today an agreement for the exclusive distribution and promotion by Invida of Ipsen's drugs Diphereline® 3.75mg & 11.25mg, Somatuline® Autogel® and Increlex® in selected countries in South-East Asia.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

Hormone News and Research

Further Reading

FDA approves new treatment option for prostate cancer

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

FDA approves Provenge prostate cancer vaccine

New theory on muscle and bone diseases

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Investigators study Pioglitazone and Vitamin E for treatment of NASH

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Potential new treatment for osteonecrosis

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Researchers link vitamin D deficiency to chronic fatigue in post-TBI sufferers

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Laughter is truly the best medicine says new research

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

Laughter increases production of antibodies and activates body's protective cells

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News